{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:02:34Z","timestamp":1788822154353,"version":"build-2803163510"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.dmpk.2026.101517","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:21:58Z","timestamp":1767889318000},"page":"101517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Quantitative prediction of human pharmacokinetic drug-drug interactions and drug clearance using humanized liver chimeric mice: a review"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0085-0577","authenticated-orcid":false,"given":"Taiji","family":"Miyake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-950X","authenticated-orcid":false,"given":"Haruka","family":"Tsutsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.dmpk.2026.101517_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142145","article-title":"Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-uPA\/SCID mice","volume":"10","author":"Tateno","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.dmpk.2026.101517_bib2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nbt1326","article-title":"Robust expansion of human hepatocytes in Fah-\/-\/Rag2-\/-\/Il2rg-\/- mice","volume":"25","author":"Azuma","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.bbrc.2011.01.042","article-title":"The reconstituted 'humanized liver' in TK-NOG mice is mature and functional","volume":"405","author":"Hasegawa","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cpt.3625","article-title":"ICH M12 drug interaction studies: summary of the efforts to achieve global convergence","volume":"118","author":"Reynolds","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2026.101517_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2025.101480","article-title":"Buffer compositions strongly impact the in vitro assessment of CYP fraction metabolized using human liver microsomes or expressed isoenzymes","volume":"62","author":"Tamemoto","year":"2025","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101517_bib6","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1124\/dmd.121.000765","article-title":"Estimation of fraction metabolized by cytochrome P450 enzymes using long-term cocultured human hepatocytes","volume":"50","author":"Klammers","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101517_bib7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/bph.16270","article-title":"Quantitative prediction of CYP3A-mediated drug-drug interactions by correctly estimating fraction metabolized using human liver chimeric mice","volume":"181","author":"Miyake","year":"2024","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/03602532.2024.2381021","article-title":"Enzyme-mediated drug-drug interactions: a review of in vivo and in vitro methodologies, regulatory guidance, and translation to the clinic","volume":"57","author":"Yadav","year":"2025","journal-title":"Drug Metab Rev"},{"issue":"11","key":"10.1016\/j.dmpk.2026.101517_bib9","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1124\/dmd.109.028969","article-title":"In vivo evaluation of drug-drug interaction via mechanism-based inhibition by macrolide antibiotics in cynomolgus monkeys","volume":"37","author":"Ogasawara","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmpk.2026.101517_bib10","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1007\/s11095-010-0157-z","article-title":"Use of in vivo animal models to assess pharmacokinetic drug-drug interactions","volume":"27","author":"Tang","year":"2010","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101517_bib11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/00498250410001685755","article-title":"Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans","volume":"34","author":"Kanazu","year":"2004","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101517_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1124\/jpet.112.198697","article-title":"Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction","volume":"344","author":"Nishimura","year":"2013","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101517_bib13","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s13318-017-0413-2","article-title":"Observation of clinically relevant drug interaction in chimeric mice with humanized livers: the case of valproic acid and carbapenem antibiotics","volume":"42","author":"Suzuki","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/tx400008g","article-title":"In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice","volume":"26","author":"Yamazaki","year":"2013","journal-title":"Chem Res Toxicol"},{"issue":"12","key":"10.1016\/j.dmpk.2026.101517_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100185","article-title":"Quantitative prediction of CYP2C9-mediated drug disposition using humanized mice","volume":"53","author":"Fujita","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101517_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100050","article-title":"Quantitative prediction of drug disposition for uridine diphosphate-glucuronosyltransferase substrates using humanized mice","volume":"53","author":"Miyake","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/bdd.2068","article-title":"A comparative evaluation of models to predict human intestinal metabolism from nonclinical data","volume":"38","author":"Yau","year":"2017","journal-title":"Biopharm Drug Dispos"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101517_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/00498254.2023.2224863","article-title":"Estimation of contribution of CYP2D6 to tipepidine metabolism in humans and prolongation of the half-life of tipepidine by combination use with a CYP2D6 inhibitor in chimeric mice with humanised liver","volume":"53","author":"Hayashi","year":"2023","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101517_bib151","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/jps.20783","article-title":"In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver","volume":"96","author":"Katoh","year":"2007","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1124\/dmd.111.042754","article-title":"Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver","volume":"40","author":"Hasegawa","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101517_bib61","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1021\/acs.chemrestox.9b00446","article-title":"Different roles of human cytochrome P450 2C9 and 3A enzymes in diclofenac 4'- and 5-Hydroxylations mediated by metabolically inactivated human hepatocytes in previously transplanted chimeric mice","volume":"33","author":"Miura","year":"2020","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.dmpk.2026.101517_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100410","article-title":"An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both Male and female animals","volume":"42","author":"Uehara","year":"2022","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.dmpk.2026.101517_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2023.100504","article-title":"Roles of human cytochrome P450 3A4\/5 in dexamethasone 6beta-hydroxylation mediated by liver microsomes and humanized liver in chimeric mice metabolically suppressed with azamulin","volume":"50","author":"Uehara","year":"2023","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"10","key":"10.1016\/j.dmpk.2026.101517_bib32","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1124\/dmd.123.001398","article-title":"Analysis of the bile acid composition in a fibroblast growth factor 19-Expressing liver-humanized mouse model and its use for CYP3A4-Mediated drug-drug interaction studies","volume":"51","author":"Mezler","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101517_bib62","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1128\/AAC.30.2.206","article-title":"Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers","volume":"30","author":"Huang","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.dmpk.2026.101517_bib63","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.2600711114","article-title":"Pharmacokinetics of probenecid following oral doses to human volunteers","volume":"71","author":"Selen","year":"1982","journal-title":"J Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101517_bib30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/00498254.2025.2518239","article-title":"Quantitative prediction of drug-drug interactions arising from CYP3A4 induction using chimeric mice with humanized liver","volume":"55","author":"Nakayama","year":"2025","journal-title":"Xenobiotica"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101517_bib64","first-page":"243","article-title":"High pressure liquid chromatographic analysis and preliminary pharmacokinetics of sulfaphenazole and its N2-glucuronide and N4-acetyl metabolites in plasma and urine of man","volume":"12","author":"Vree","year":"1990","journal-title":"Pharm World Sci"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101517_bib65","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF03189454","article-title":"Metabolism of tienilic acid (ticrynafen) in man. Pharmacokinetic and mass spectrometric studies","volume":"5","author":"Vinay","year":"1980","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1124\/dmd.117.075994","article-title":"Organic anion-transporting polypeptide (OATP)-mediated drug-drug interaction study between rosuvastatin and cyclosporine A in chimeric mice with humanized liver","volume":"46","author":"Uchida","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmpk.2026.101517_bib42","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1016\/j.xphs.2019.03.021","article-title":"Effect of rifampicin on the plasma concentrations of bile Acid-O-Sulfates in monkeys and human liver-transplanted chimeric mice with or without bile flow diversion","volume":"108","author":"Takehara","year":"2019","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib66","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1378\/chest.115.1.12","article-title":"Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids","volume":"115","author":"Peloquin","year":"1999","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101517_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1124\/jpet.123.001595","article-title":"Quantitative prediction of OATP-mediated disposition and biliary clearance using human liver chimeric mice","volume":"387","author":"Miyake","year":"2023","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101517_bib40","first-page":"2598","article-title":"Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans","volume":"6","author":"van Zuylen","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101517_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70017","article-title":"Plasma and urinary CP I and CP III concentrations in chimeric mice with human hepatocytes after rifampicin administration","volume":"12","author":"Shishido","year":"2024","journal-title":"Pharmacol Res Perspect"},{"issue":"10","key":"10.1016\/j.dmpk.2026.101517_bib38","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1124\/dmd.124.001792","article-title":"Utility of chimeric mice with humanized livers for predicting hepatic organic anion-transporting polypeptide 1B-Mediated clinical drug-drug interactions","volume":"52","author":"Feng","year":"2024","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2026.101517_bib19","series-title":"The 38th Annual Meeting of the Japanese Society for the Study of Xenobiotics 25-29","article-title":"Predictability of hepatic metabolism-mediated drug-drug interaction in clinical with use of PXB mice","author":"Hamada","year":"2023"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101517_bib21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/cpt.2384","article-title":"Model-based drug-drug interaction extrapolation strategy from adults to children: risdiplam in pediatric patients with spinal muscular atrophy","volume":"110","author":"Cleary","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/dmd.120.000055","volume":"49","author":"Wong","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib23","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1248\/bpb.b20-00578","article-title":"Evaluation of methods to assess CYP3A induction risk in clinical practice using in vitro induction parameters","volume":"44","author":"Tsutsui","year":"2021","journal-title":"Biol Pharm Bull"},{"issue":"8","key":"10.1016\/j.dmpk.2026.101517_bib24","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/00498254.2019.1710620","article-title":"Quantitative evaluation of hepatic and intestinal induction of CYP3A in clinical practice","volume":"50","author":"Tsutsui","year":"2020","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1124\/dmd.109.029637","article-title":"Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction","volume":"38","author":"Kim","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmpk.2026.101517_bib26","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s11095-017-2246-8","article-title":"Strategy for CYP3A induction risk assessment from preclinical signal to human: a case example of a late-stage discovery compound","volume":"34","author":"Mao","year":"2017","journal-title":"Pharm Res"},{"issue":"10","key":"10.1016\/j.dmpk.2026.101517_bib27","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1124\/dmd.110.032656","article-title":"Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys","volume":"38","author":"Ohtsuka","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/ijms15010058","article-title":"Chimeric mice with humanized livers: a unique tool for in vivo and in vitro enzyme induction studies","volume":"15","author":"Kakuni","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dmpk.2026.101517_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2024.101010","article-title":"Quantitative prediction of CYP3A induction-mediated drug-drug interactions in clinical practice","volume":"57","author":"Tsutsui","year":"2024","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101517_bib34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI6663","article-title":"The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin","volume":"104","author":"Greiner","year":"1999","journal-title":"J Clin Investig"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101517_bib35","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1124\/dmd.123.001587","volume":"52","author":"Rollison","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1124\/dmd.121.000695","article-title":"Cynomolgus monkey as an emerging animal model to study drug transporters: in vitro, in vivo, in vitro-to-in vivo translation","volume":"50","author":"Shen","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmpk.2026.101517_bib37","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1124\/dmd.118.081794","article-title":"Simultaneous assessment of transporter-mediated drug-drug interactions using a probe drug cocktail in cynomolgus monkey","volume":"46","author":"Kosa","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101517_bib44","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40262-020-00867-1","article-title":"Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug-drug interaction studies","volume":"59","author":"Elmeliegy","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101517_bib45","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/psp4.12807","article-title":"Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney","volume":"11","author":"Asaumi","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mcp.2003.27","article-title":"P-glycoprotein-mediated intestinal and biliary digoxin transport in humans","volume":"73","author":"Drescher","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101517_bib47","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/dmd.111.040923","article-title":"Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver","volume":"40","author":"Sanoh","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib147","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF01106706","article-title":"A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations","volume":"14","author":"Roberts","year":"1986","journal-title":"J Pharmacokinet Biopharm"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib67","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/labinvest.2012.158","article-title":"Morphological and microarray analyses of human hepatocytes from xenogeneic host livers","volume":"93","author":"Tateno","year":"2013","journal-title":"Lab Invest"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101517_bib68","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2353\/ajpath.2010.090430","article-title":"Hepatic hyperplasia associated with discordant xenogeneic parenchymal-nonparenchymal interactions in human hepatocyte-repopulated mice","volume":"177","author":"Utoh","year":"2010","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101517_bib69","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/00498254.2018.1460516","article-title":"Prediction of human pharmacokinetics of typical compounds by a physiologically based method using chimeric mice with humanized liver","volume":"49","author":"Nakayama","year":"2019","journal-title":"Xenobiotica"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101517_bib71","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.dmpk.2020.07.004","article-title":"Human plasma concentration-time profiles of troglitazone and troglitazone sulfate simulated by in vivo experiments with chimeric mice with humanized livers and semi-physiological pharmacokinetic modeling","volume":"35","author":"Ito","year":"2020","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101517_bib72","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.dmpk.2020.05.004","article-title":"Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data","volume":"35","author":"Nakayama","year":"2020","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101517_bib73","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.dmpk.2026.101517_bib74","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.tiv.2006.06.003","article-title":"Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements","volume":"20","author":"Sohlenius-Sternbeck","year":"2006","journal-title":"Toxicol Vitro"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101517_bib75","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/00498254.2015.1007112","article-title":"Predictability of plasma concentration-time curves in humans using single-species allometric scaling of chimeric mice with humanized liver","volume":"45","author":"Sanoh","year":"2015","journal-title":"Xenobiotica"},{"issue":"12","key":"10.1016\/j.dmpk.2026.101517_bib50","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1080\/00498254.2016.1265160","article-title":"Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver","volume":"47","author":"Miyamoto","year":"2017","journal-title":"Xenobiotica"},{"issue":"12","key":"10.1016\/j.dmpk.2026.101517_bib52","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1080\/00498254.2019.1579394","article-title":"Prediction of human pharmacokinetics of long half-life compounds using chimeric mice with humanised liver","volume":"49","author":"Miyamoto","year":"2019","journal-title":"Xenobiotica"},{"issue":"11","key":"10.1016\/j.dmpk.2026.101517_bib51","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1080\/00498254.2020.1769229","article-title":"Predictability of human pharmacokinetics of drugs that undergo hepatic organic anion transporting polypeptide (OATP)-mediated transport using single-species allometric scaling in chimeric mice with humanized liver: integration with hepatic drug metabolism","volume":"50","author":"Sanoh","year":"2020","journal-title":"Xenobiotica"},{"issue":"9","key":"10.1016\/j.dmpk.2026.101517_bib77","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/00498254.2021.1950865","article-title":"Empirical and theoretical approaches for the prediction of human hepatic clearance using chimeric mice with humanised liver: the use of physiologically based scaling, a novel solution for potential overprediction due to coexisting mouse metabolism","volume":"51","author":"Matsumoto","year":"2021","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib76","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/cts.13070","article-title":"Prediction of human pharmacokinetics for low-clearance compounds using pharmacokinetic data from chimeric mice with humanized livers","volume":"15","author":"Yoshida","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/00498254.2020.1808735","article-title":"Characterization of plasma protein binding in two mouse models of humanized liver, PXB mouse and humanized TK-NOG mouse","volume":"51","author":"Miyamoto","year":"2021","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101517_bib49","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4155\/bio-2021-0250","article-title":"Simultaneous measurement of mouse and human albumin in chimeric mice with humanized livers","volume":"14","author":"Landry","year":"2022","journal-title":"Bioanalysis"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101517_bib53","first-page":"957","article-title":"Pharmacokinetic theory of cassette dosing in drug discovery screening","volume":"29","author":"White","year":"2001","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib78","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1021\/jm901371v","article-title":"Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination","volume":"53","author":"Varma","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.dmpk.2026.101517_bib79","unstructured":"NMS Labs. Clinical example report: proventil (albuterol sulfate), sample ID 16001526-001."},{"key":"10.1016\/j.dmpk.2026.101517_bib80","unstructured":"Dey Laboratories. Drug approval package: accuneb (albuterol sulfate) inhalation solution 0.042% and 0.021%, NDA 20-949. U.S. Food and Drug Administration, Center for Drug Evaluation and Research."},{"issue":"11","key":"10.1016\/j.dmpk.2026.101517_bib81","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101517_bib82","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/0091270012440282","article-title":"Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance","volume":"53","author":"Lombardo","year":"2013","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101517_bib83","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/dmd.114.059311","article-title":"Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone","volume":"43","author":"Chen","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101517_bib84","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00562807","article-title":"Pharmacokinetics of amiodarone after intravenous and oral administration","volume":"19","author":"Andreasen","year":"1981","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib85","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00380-010-0047-7","article-title":"Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects","volume":"26","author":"Shiga","year":"2011","journal-title":"Heart Vessel"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101517_bib86","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2125.1979.tb01040.x","article-title":"Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers","volume":"8","author":"Danhof","year":"1979","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.dmpk.2026.101517_bib87","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/psp4.12355","article-title":"A strategy to refine the phenotyping approach and its implementation to predict drug clearance: a physiologically based pharmacokinetic simulation study","volume":"7","author":"Adiwidjaja","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101517_bib88","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/1049909115612800","article-title":"Aripiprazole:A new option in delirium","volume":"34","author":"Prommer","year":"2017","journal-title":"Am J Hosp Palliat Med"},{"key":"10.1016\/j.dmpk.2026.101517_bib89","unstructured":"Pfizer Europe MA EEIG. Summary of product characteristics: Conbriza (bazedoxifene) 20 mg film-coated tablets, EU\/1\/09\/511. European Medicines Agency, European Commission."},{"issue":"5","key":"10.1016\/j.dmpk.2026.101517_bib90","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.1998.16.5.1803","article-title":"O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings","volume":"16","author":"Dolan","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dmpk.2026.101517_bib91","unstructured":"Actelion Registration Ltd. Scientific discussion: tracleer (Bosentan) 62.5 mg and 125 mg film-coated tablets, EU\/1\/02\/196. European Medicines Agency, Committee for medicinal products for human use."},{"issue":"5","key":"10.1016\/j.dmpk.2026.101517_bib92","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/bdd.2265","article-title":"Effects of low temperature on blood-to-plasma ratio measurement","volume":"42","author":"Novak","year":"2021","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib93","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00563556","article-title":"Absolute bioavailability of chlorthalidone in man: a cross-over study after intravenous and oral administration","volume":"15","author":"Fleuren","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101517_bib94","unstructured":"Hoffmann-La Roche Inc. U.S. Food and Drug Administration, 17-533. Bureau of Drugs."},{"issue":"8","key":"10.1016\/j.dmpk.2026.101517_bib95","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s11095-008-9607-2","article-title":"The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling","volume":"25","author":"Kato","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.dmpk.2026.101517_bib96","unstructured":"Kyorin Pharmaceutical Co. L. Interview form: prednisolone (prednisolone) tablets 5mg \u201cMita\u201d, approval no. 21800AMX10301000. Pharmaceuticals and medical devices agency. Japan: Ministry of Health, Labour and Welfare."},{"key":"10.1016\/j.dmpk.2026.101517_bib97","unstructured":"Asahi Kasei Pharma Corp. Interview form: Famvir (famciclovir) tablets 250 mg, Approval No. 22000AMY00003. Pharmaceuticals and medical devices agency. Japan: Ministry of Health, Labour and Welfare."},{"key":"10.1016\/j.dmpk.2026.101517_bib98","unstructured":"G. D. Searle & Co. Drug approval package: norpace (disopyramide phosphate) capsules 100 mg and 150 mg (base), NDA 17-447. U.S. Food and Drug Administration, Bureau of Drugs."},{"issue":"4","key":"10.1016\/j.dmpk.2026.101517_bib99","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10928-024-09912-z","article-title":"Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions","volume":"51","author":"Li","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.dmpk.2026.101517_bib100","unstructured":"Sanofi Winthrop Industrie. Summary of product characteristics: TAXOTERE (docetaxel) 20 mg\/0.5 ml concentrate and solvent for solution for infusion, EU\/1\/95\/002\/001. European Medicines Agency."},{"key":"10.1016\/j.dmpk.2026.101517_bib101","unstructured":"Hoechst Marion Roussel Inc. Drug Approval Package: anzemet (dolasetron mesylate) tablets, NDA 20-623. U.S. Food and Drug Administration. Center for Drug Evaluation and Research."},{"issue":"14","key":"10.1016\/j.dmpk.2026.101517_bib102","doi-asserted-by":"crossref","first-page":"78g","DOI":"10.1016\/0002-9149(87)90162-7","article-title":"Pharmacokinetic overview of doxazosin","volume":"59","author":"Elliott","year":"1987","journal-title":"Am J Cardiol"},{"issue":"11\u201312","key":"10.1016\/j.dmpk.2026.101517_bib103","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s002280050709","article-title":"Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke","volume":"55","author":"Hoke","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101517_bib104","unstructured":"Eli Lilly & Company. Drug Approval Package: gemzar (gemcitabine HCl) for injection 200 mg\u30fb1 g, NDA 20-509. U.S. Food and Drug Administration, Center for Drug Evaluation and Research."},{"key":"10.1016\/j.dmpk.2026.101517_bib105","unstructured":"Orphan Europe. Scientific discussion: pedea (ibuprofen) solution for injection 5 mg\/mL, EU\/1\/04\/284\/001. European Medicines Agency, Committee for medicinal products for human use."},{"issue":"5","key":"10.1016\/j.dmpk.2026.101517_bib106","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1124\/dmd.110.037457","article-title":"Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach","volume":"39","author":"Deguchi","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101517_bib107","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/jat\/bku034","article-title":"Variability in metabolism of imipramine and desipramine using urinary excretion data","volume":"38","author":"Ramey","year":"2014","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.dmpk.2026.101517_bib108","unstructured":"Iroko Pharmaceuticals L. U.S. Food and Drug Administration, 204-768. Center for Drug Evaluation and Research."},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib109","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00544018","article-title":"Pharmacokinetics of ketanserin in man","volume":"25","author":"Reimann","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/bdd.2510140109","article-title":"Blood to plasma ratio of mefloquine: interpretation and pharmacokinetic implications","volume":"14","author":"Tajerzadeh","year":"1993","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib111","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2165\/00003495-199345030-00009","article-title":"Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy","volume":"45","author":"Palmer","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.dmpk.2026.101517_bib112","unstructured":"Bayer Corporation. Clinical Pharmacology and Biopharmaceutics Review: avelox (moxifloxacin hydrochloride) oral tablets 400 mg, NDA 21-085. U.S. Food and Drug Administration, Center for Drug Evaluation and Research."},{"key":"10.1016\/j.dmpk.2026.101517_bib113","unstructured":"Novartis Pharmaceuticals Corp. U.S. Food and Drug Administration, 50-791. Center for Drug Evaluation and Research."},{"key":"10.1016\/j.dmpk.2026.101517_bib114","unstructured":"Alkermes Inc. Pharmacology\/Toxicology Review: vivitrol (naltrexone for extended-release injectable suspension) 380 mg\/vial, NDA 21-897. U.S. Food and Drug Administration. Center for Drug Evaluation and Research."},{"issue":"6","key":"10.1016\/j.dmpk.2026.101517_bib115","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/clpt.1984.105","article-title":"Nifedipine: kinetics and dynamics in healthy subjects","volume":"35","author":"Kleinbloesem","year":"1984","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101517_bib116","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2125.1987.tb03214.x","article-title":"Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration","volume":"24","author":"Mikus","year":"1987","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101517_bib117","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s11095-021-03036-6","article-title":"Dried blood spot technique applied in therapeutic drug monitoring of anticancer drugs: a review on conversion methods to correlate plasma and dried blood spot concentrations","volume":"38","author":"Iacuzzi","year":"2021","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101517_bib118","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3109\/00498254.2012.734642","article-title":"Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer","volume":"43","author":"Deng","year":"2013","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib119","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1006408415431","article-title":"Disposition kinetics and urinary excretion of pefloxacin after intravenous injection in crossbred calves","volume":"24","author":"Srivastava","year":"2000","journal-title":"Vet Res Commun"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/psp4.12737","article-title":"Physiologically based pharmacokinetic modeling for dose optimization of quinine-phenobarbital coadministration in patients with cerebral malaria","volume":"11","author":"Sae-Heng","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2\u20133","key":"10.1016\/j.dmpk.2026.101517_bib121","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/j.1552-4604.1982.tb02662.x","article-title":"Phenobarbital pharmacokinetics and bioavailability in adults","volume":"22","author":"Nelson","year":"1982","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.dmpk.2026.101517_bib122","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/j.1552-4604.1988.tb05725.x","article-title":"Lack of effect of cholestyramine on phenytoin bioavailability","volume":"28","author":"Barzaghi","year":"1988","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101517_bib123","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/clpt.1980.235","article-title":"Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects","volume":"28","author":"Perucca","year":"1980","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib124","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1248\/bpb.b18-00582","article-title":"Prediction of human hepatic clearance for cytochrome P450 substrates via a new culture method using the collagen vitrigel membrane Chamber and fresh hepatocytes isolated from liver humanized mice","volume":"42","author":"Watari","year":"2019","journal-title":"Biol Pharm Bull"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101517_bib125","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/psp4.12181","article-title":"Pharmacokinetics of sulfadoxine and pyrimethamine for intermittent preventive treatment of malaria during pregnancy and after delivery","volume":"6","author":"de Kock","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101517_bib126","unstructured":"GlaxoSmithKline. Prescribing information: zantac (ranitidine hydrochloride) injection 25 mg\/mL and injection premixed 50 mg\/50 mL. U.S. Food and Drug Administration. Center for Drug Evaluation and Research."},{"issue":"5","key":"10.1016\/j.dmpk.2026.101517_bib127","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/00912700022009251","article-title":"Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency","volume":"40","author":"Coulomb","year":"2000","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib128","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1208\/s12248-023-00800-x","article-title":"In Vitro-In vivo extrapolation and scaling factors for clearance of human and preclinical species with liver microsomes and hepatocytes","volume":"25","author":"Tess","year":"2023","journal-title":"AAPS J"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101517_bib129","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003088-200241070-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of repaglinide","volume":"41","author":"Hatorp","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101517_bib130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2165\/00003088-199732060-00002","article-title":"Clinical pharmacokinetics of sulindac. A dynamic old drug","volume":"32","author":"Davies","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2026.101517_bib131","unstructured":"Glaxo Wellcome Inc. Rug Approval Package: imitrex (sumatriptan) nasal spray 5 mg, 10 mg, and 20 mg, NDA 20-626. U.S. Food and Drug Administration. Center for Drug Evaluation and Research."},{"key":"10.1016\/j.dmpk.2026.101517_bib132","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fphar.2012.00092","article-title":"Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new Insight into the tamoxifen mass balance","volume":"3","author":"Dickschen","year":"2012","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib133","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3999\/jscpt.15.399","article-title":"Pharmacokinetics of tenoxicam in healthy volunteers and elderly patients","volume":"15","author":"Kobayashi","year":"1984","journal-title":"Rinsho yakuri\/Japanese Journal of Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.dmpk.2026.101517_bib134","unstructured":"Hospira I. Prescribing information: theophylline in 5% Dextrose Injection, USP (theophylline). 200 mg, 400 mg, and 800 mg. U.S. Food and Drug Administration. Center for Drug Evaluation and Research."},{"key":"10.1016\/j.dmpk.2026.101517_bib135","unstructured":"Merck Sharp & Dohme Laboratories. Statistical Review and Evaluation: Blocadren (timolol maleate) tablets 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, NDA 18-017. U.S. Food and Drug Administration, Center for Drug Evaluation and Research."},{"issue":"5","key":"10.1016\/j.dmpk.2026.101517_bib136","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1177\/00912700022009161","article-title":"Lack of interaction between tolcapone and tolbutamide in healthy volunteers","volume":"40","author":"Jorga","year":"2000","journal-title":"J Clin Pharmacol"},{"issue":"2 Pt 1","key":"10.1016\/j.dmpk.2026.101517_bib137","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/1078-0432.664.11.2","article-title":"A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors","volume":"11","author":"Dees","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.dmpk.2026.101517_bib138","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/dmd.120.000133","article-title":"Application of the Extended Clearance Classification system (ECCS) in drug discovery and development: selection of appropriate in vitro tools and clearance prediction","volume":"48","author":"Umehara","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2026.101517_bib139","unstructured":"Eisai Co L. Interview form: warfarin potassium tablets 0.5 mg, 1 mg, and 5 mg; warfarin potassium granules 0.2 %. Pharmaceuticals and medical devices agency, Japan."},{"issue":"6","key":"10.1016\/j.dmpk.2026.101517_bib140","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00003088-198611060-00005","article-title":"Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship","volume":"11","author":"Holford","year":"1986","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.dmpk.2026.101517_bib141","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1124\/dmd.110.033555","article-title":"In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase","volume":"38","author":"Zientek","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101517_bib142","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10637-006-9024-5","article-title":"A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor","volume":"25","author":"Alousi","year":"2007","journal-title":"Invest N Drugs"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101517_bib143","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00280-004-0962-3","article-title":"Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions","volume":"56","author":"Anderson","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101517_bib144","first-page":"349","article-title":"Quantitation of zolpidem in biological fluids by electro-driven microextraction combined with HPLC-UV analysis","volume":"17","author":"Yaripour","year":"2018","journal-title":"Excli j"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101517_bib145","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1124\/dmd.109.030783","article-title":"Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences","volume":"38","author":"Dalvie","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2026.101517_bib54","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2017.05.014","article-title":"Molecular properties associated with transporter-mediated drug disposition","volume":"116","author":"Varma","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"10.1016\/j.dmpk.2026.101517_bib148","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1007\/s11095-015-1749-4","article-title":"Predicting clearance mechanism in drug discovery: Extended clearance Classification System (ECCS)","volume":"32","author":"Varma","year":"2015","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101517_bib149","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/cpt1977214430","article-title":"Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease","volume":"21","author":"Klotz","year":"1977","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-19242-0","article-title":"Humanized liver TK-NOG mice with functional deletion of hepatic murine cytochrome P450s as a model for studying human drug metabolism","volume":"12","author":"Uehara","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41467-017-00049-x","article-title":"A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism","volume":"8","author":"Barzi","year":"2017","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.dmpk.2026.101517_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101466","article-title":"Species-specific gene expression manipulation in humanized livers of chimeric mice via siRNA-encapsulated lipid nanoparticle treatment","volume":"33","author":"Yamazaki","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"10.1016\/j.dmpk.2026.101517_bib58","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1124\/dmd.115.063479","article-title":"Development of murine Cyp3a Knockout chimeric mice with humanized liver","volume":"43","author":"Kato","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101517_bib59","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.gastro.2015.05.043","article-title":"Fibroblast growth factor signaling controls liver size in mice with humanized livers","volume":"149","author":"Naugler","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101517_bib146","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/bdd.1990","article-title":"Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans","volume":"37","author":"Nakada","year":"2016","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101517_bib60","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s00204-025-03986-5","article-title":"Development of human growth hormone-treated chimeric mice with humanized livers for an evaluation model of drug-induced fatty liver disease","volume":"99","author":"Morioka","year":"2025","journal-title":"Arch Toxicol"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436726000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436726000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:17:31Z","timestamp":1774250251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436726000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":149,"alternative-id":["S1347436726000030"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2026.101517","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative prediction of human pharmacokinetic drug-drug interactions and drug clearance using humanized liver chimeric mice: a review","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2026.101517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101517"}}